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†Department of Drug Design, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
‡Chemistry Department, Faculty of Science, Sohag University, Sohag, 82524, Egypt
§Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland
*S Supporting Information
ABSTRACT: The direct nonpeptidic macrocycle synthesis of
α-isocyano-ω-amines via the classical Ugi four-component
reaction (U-4CR) is introduced. Herein an eﬃcient and
ﬂexible two-step procedure to complex macrocycles is
reported. In the ﬁrst step, the reaction between unprotected
diamines and isocyanocarboxylic acids gives high diversity of
unprecedented building blocks in high yield. In the next step,
the α-isocyano-ω-amines undergo a U-4CR with high diversity
of aldehydes and carboxylic acids in a one-pot procedure. This
synthetic approach is short and eﬃcient and leads to a wide
range of macrocycles with diﬀerent ring sizes.
■ INTRODUCTION
The Ugi four-component reaction (U-4CR) is a widely used
multicomponent reaction (MCR) to provide a general route to
diverse peptides, macrocycles, and other complex small
molecules.1,2 This reaction has emerged as a powerful synthetic
method for organic and pharmaceutical targets. Among MCRs,
isocyanide-based multicomponent reactions (IMCRs) play an
important role in pharmaceutical and drug discovery
research3−7 and provide access to more diverse, complex, and
novel scaﬀolds including small molecules and macrocycles.
Macrocycles as intermediates between small molecules and
biologics are useful to target ﬂat, large, and featureless protein−
protein interfaces.8,9 Artiﬁcial macrocycles promise to provide
better control over synthesizability and over their physico-
chemical properties resulting in drug-like properties. However,
there are only very few general and short synthetic routes
toward macrocycles. Therefore, we report here such a general
and short two-step synthesis of macrocycles using the Ugi
reaction.
Macrocycles can be synthesized through MCRs by using
bifunctional substrates. Failli et al. ﬁrst used N,C-unprotected
tri- and hexapeptides to synthesize bioactive cyclic hexapep-
tides.10 Wessjohann et al. used homobifunctional starting
materials to synthesize macrocycles using Ugi reactions.11
Yudin et al. introduced formylaziridines as bifunctional Ugi
starting materials to synthesize spectacular macrocycles.12,13
Recently, Dömling et al. has shown the great impact of the
direct use of bifunctional substrates such as α-isocyano-ω-
carboxylic acids14 and α-carboxylic acid-ω-amines15 in macro-
cycle synthesis via the Ugi reaction (Figure 1). Of all six
possible permutations of bifunctional substrates for macro-
cyclizations via the Ugi reaction, three have been already
realized, while the last three still deserve validation: α-isocyano-
ω-carboxylic acids, α-carboxylic acid-ω-amines, α-isocyano-ω-
amines, α-carboxylic acid-ω-aldehydes, α-isocyano-ω-aldehyde,
and α-amino-ω-aldehydes. In light of our extended research
interest in MCRs and our previous experience in the chemistry
of macrocycles, herein we report the use of α-isocyano-ω-amine
for the synthesis of macrocycles via the Ugi-macrocyclization
reaction.
■ RESULTS AND DISCUSSION
The ﬁrst step of our current work is an extension of our recent
report on using α-isocyano-ω-amines as building blocks in the
cyclization reaction.16 We started our study by the synthesis of
amino isocyanides via coupling of diamines with isocyanide
esters under protecting group free conditions. Their synthesis
and isolation is demanding due to the highly polar nature of
α,ω-amino isocyanides. Therefore, various solvents such as
chloroform, dichloromethane (DCM), methanol, water,
tetrahydrofuran, ethanol, and triﬂuoroethanol were tested at
room temperature (Table 1). Screening of diﬀerent solvents
revealed that dioxane was the best solvent for this process.
Puriﬁcation was performed by preparative column chromatog-
raphy on silica (60−200 μm) using 1:1 dichloromethane:ethyl
acetate as eluent A and ammonia in methanol 5% as eluent B in
a gradient method. Under the optimized conditions, ten α-
isocyano-ω-amines of diﬀerent lengths were synthesized from
commercially available diamines in good purity and yields, each
on a gram scale (Scheme 1).
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In the next step, the macrocyclic ring closure was carried out
by an U-4CR under optimized conditions using 1 equiv of an
oxo component and an acid (Scheme 2). The optimization was
performed by using N-(5-aminopentyl)-5-isocyanopentana-
mide, paraformaldehyde, and 2-phenylacetic acid as a model
reaction. The reaction did not proceed in 1.0 M methanol
solution. The same reaction was carried out in diﬀerent
dilutions of methanol, and it was found that a highly diluted
0.01 M equimolar mixture of reactants in methanol gives the
15-membered macrocycle 6a in good yields (60%). Although
triﬂuoroethanol (65% yield) was slightly superior to MeOH, we
chose MeOH for further scope and limitation studies due to the
higher price of TFE. Polar aprotic solvents such as THF and
CH3CN gave the product in moderate yields of 30% and 22%,
respectively, at room temperature. Next, diﬀerent Lewis acids
such as ZnCl2 in MeOH and TFE as a solvent were screened. It
was found that ZnCl2 in MeOH aﬀords product in good yield
(43%). Under sonication conditions, however, the reaction led
to low yield of the product (Table 1).
With the optimized reaction conditions in hand, the scope
and limitations of the Ugi-macrocyclization reaction were
further investigated by synthesizing 15 diﬀerent macrocycles
(12−17 membered ring size) which are shown in Scheme 2. In
this reaction, several commercially available carboxylic acids,
aliphatic and aromatic aldehydes, and ketones as oxo-
components assemble to aﬀord macrocyclic derivatives in
good yields of 33−74% after puriﬁcation by column
chromatography. With aliphatic aldehydes, product was
obtained in good yields, up to 50%; however, aliphatic
carboxylic acids such as isobutyric acid, butyric acid, and
pivalic acid resulted in only trace amounts of product.
To investigate potential intramolecular hydrogen bonds of
our compounds, a sulfur-containing macrocycle was treated
with m-chloroperbenzoic acid (mCPBA) in DCM to aﬀord
sulfoxide and sulfone. As an example, the reaction of
macrocycle 6m with 1 equiv and 4 equiv of mCPBA in DCM
aﬀorded sulfoxide 7a and sulfone 7b in good yields of 65% and
Figure 1. Six theoretical possibilities for macrocycle synthesis by
classical Ugi 4-CR.
Table 1. Optimization of Ugi-4CR
entry solvent (M) time (h) catalyst/conditions yield (%)c
1 MeOH (1.0) 12 rt traces
2 MeOH (0.1) 12 rt 15
3 MeOH (0.01) 12 rt 48
4 TFE (0.01) 12 rt 65
5 CH3CN (0.01) 12 rt 22
6 THF (0.01) 12 rt 30
7b MeOH (0.01) 12 ZnCl2 43
8b TFE (0.01) 12 ZnCl2 25
9 MeOH (0.01) 24 rt 60
10 MeOH (0.01) 12 sonication 20
aThe reaction was carried out with N-(5-aminopentyl)-5-isocyano-
pentanamide (1.0 mmol), paraformaldehyde (1.0 mmol), and 2-
phenylacetic acid (1.0 mmol). b10 mol % catalyst used. cYield of
isolated product.
Scheme 1. Synthesized α,ω-Amino Isocyanides with
Corresponding Yields
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77%, respectively, after 4 h. As shown in Scheme 3, these
sulfoxide and sulfone functional groups are potentially capable
to form amide−sulfoxide and amide−sulfone intramolecular
hydrogen bonds leading to lower energy conformations of the
corresponding macrocycles with interlocked structures which
could have a signiﬁcant impact on biological membrane
permeability.
X-ray crystal structures of several macrocycles with diﬀerent
sizes and substituents can further provide some ﬁrst insight into
possible solid-state conformations (Figure 2). For instance,
compound 6l shows an intramolecular hydrogen bonding.
Physicochemical properties are of high importance for the
development of drug-like compounds. What is the property
proﬁle of our macrocycles? To answer this question, we
constructed a random virtual 1000 macrocycle library (SI). We
calculated some properties of the library related to drug-
likeliness including molecular weight, lipophilicity, number of
hydrogen bond donors and acceptors, number of rotatable
bonds, polar surface area, and moment of inertia (Figure 3).
Interestingly, analysis of the library shows that 21% obey the
Lipinski rule of 5 (RO5). The cLogP vs MW distribution of a
considerable fraction of the chemical space is favorable drug-
like with an average MW and cLogP of 572 and 4.1,
respectively.
Moreover, punctual analysis of 3D modeled representatives
and X-ray structures underline the nonﬂat shapes of the
medium sized rings. Overall, a considerable fraction of our
macrocyclic space is predicted to have drug-like properties. This
is in accordance with the recent proposal that the chemical
space from 500 to 1000 Da remains virtually unexplored and
represents a vast opportunity for those prepared to venture into
new territories of drug discovery.17,18
■ CONCLUSIONS
A very mild, straightforward, two-step, rapid, and highly diverse
macrocycle (12−17 membered) synthesis pathway via MCRs
was introduced. In this strategy, macrocyclic ring closure was
performed through Ugi-4CR to aﬀord novel complex
compounds with potentially biological and pharmaceutical
importance. Moreover, our strategy will allow a unique simple
route for the synthesis of nonpeptidic macrocycles. Other
macrocyclic scaﬀolds obtained from diﬀerent combinations of
MCRs and their applications as inhibitors for protein−protein
interactions are currently being investigated in our laboratory
and will be reported shortly.
■ EXPERIMENTAL SECTION
General Methods. All chemicals were purchased from commercial
suppliers and used without any puriﬁcation unless otherwise noted.
Nuclear magnetic resonance spectra were recorded. Chemical shifts for
1H NMR are reported as δ values, and coupling constants are in hertz
(Hz). The following abbreviations are used for spin multiplicity: s =
singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, quin =
quintet, dd = double of doublets, ddd = double of doublet of doublets,
m = multiplet. Chemical shifts for 13C NMR reported in ppm relative
to the solvent peak. Thin layer chromatography was performed on
silica gel plates (0.20 mm thick, particle size 25 μm). Flash
chromatography was performed using RediSep Rf normal-phase silica
Scheme 2. Synthesized Macrocycles with Corresponding
Yields
Scheme 3. Selective Oxidative Modiﬁcations of a Sulfur-
Containing Macrocycle
Figure 2. X-ray crystal structure of some synthesized macrocyles.
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ﬂash columns (silica gel 60 Å, 230−400 mesh). Electrospray ionization
mass spectra (ESI-MS) were recorded.
Procedure and Analytical Data for Synthesis of α-Isocyano-ω-
amine. A round-bottom ﬂask was charged with a magnet stirrer, the
diamine (6.0 equiv), and the α-isocyano-ω-methyl ester (5.0 equiv),
and 1,4-dioxane (0.1 M) was added. The reaction mixture was stirred
at room temperature overnight. The solvent was removed under
reduced pressure, and the residue was puriﬁed by column
chromatography on silica (eluent: 0−100% AB; A 1:1 mixture of
EtOAc:DCM, B: methanol, next with C: methanol containing 5%
concd aq ammonia, particle size: 40−63 μm).
N-(5-Aminopentyl)-5-isocyanopentanamide 3a. The product was
obtained as an oil (55%, 0.580 g). 1H NMR (500 MHz, CDCl3) δ 6.58
(t, J = 5.8 Hz, 1H), 3.41−3.34 (m, 2H), 3.15 (q, J = 6.7 Hz, 2H), 2.65
(t, J = 7.1 Hz, 2H), 2.16 (t, J = 7.0 Hz, 2H), 1.74−1.61 (m, 4H), 1.49−
1.38 (m, 4H), 1.33−1.24 (m, 2H). 13C NMR (126 MHz, CDCl3) δ
172.3, 155.6, 41.4, 39.2, 35.2, 32.1, 29.2, 28.5, 24.0, 22.5. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C11H22N3O 212.1758; found
212.1757.
N-(3-Aminopropyl)-6-isocyanohexanamide 3b.16 The product
was obtained as an oil (60%, 0.591 g). 1H NMR (500 MHz,
CDCl3) δ 6.62 (bs, 1H), 3.42−3.36 (m, 2H), 3.36−3.29 (m, 2H), 2.77
(t, J = 6.4 Hz, 2H), 2.18 (t, J = 7.5 Hz, 2H), 1.72−1.59 (m, 6H), 1.51−
1.42 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 172.8, 155.6, 50.2,
41.5, 39.8, 37.7, 36.3, 32.2, 28.8, 25.9.
N-(4-Aminobutyl)-3-isocyanopropanamide 3c.16 The product
was obtained as an oil (60%, 0.464 g). 1H NMR (500 MHz,
CD3OD) δ 3.78 (t, J = 6.3 Hz, 2H), 3.26 (t, J = 6.5 Hz, 2H), 2.73 (t, J
= 6.5 Hz,, 2H), 2.66−2.51 (m, 2H), 1.64−1.51 (m, 4H); 13C NMR
(126 MHz, CD3OD) δ 171.6, 156.8, 42.0, 40.3, 39.1, 36.7, 30.3, 27.9.
N-(2-((2-Aminoethyl)thio)ethyl)-3-(1H-indol-3-yl)-2-isocyanopro-
panamide 3d.16 The product was obtained as an oil (49%, 0.774 g).
1H NMR (500 MHz, CD3OD) δ 7.58 (d, J = 8.0 Hz, 1H), 7.36 (d, J =
8.0 Hz, 1H), 7.20 (s, 1H), 7.10 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz,
1H), 4.56 (t, J = 6.6 Hz, 1H), 3.40−3.35 (m, 2H), 3.32 (p, J = 1.6 Hz,
1H), 3.29−3.18 (m, 2H), 2.72 (t, J = 6.6 Hz, 2H), 2.51 (t, J = 6.6 Hz,
2H), 2.32 (t, J = 7.1 Hz, 2H); 13C NMR (126 MHz, methanol-d4) δ
167.1, 158.4, 136.6, 127.1, 123.9, 121.2, 118.6, 118.0, 111.0, 107.7,
58.3, 40.1, 39.1, 33.7, 29.7, 29.5.
N-(6-Aminohexyl)-2-isocyano-3-phenylpropanamide 3e.16 The
product was obtained as an oil (56%, 0.764 g). 1H NMR (500
MHz, CD3OD) δ 7.42−7.23 (m, 5H), 3.34 (t, J = 1.7 Hz, 1H), 3.28−
3.09 (m, 4H), 2.67 (t, J = 7.2 Hz, 2H), 1.57−1.41 (m, 4H), 1.40−1.31
(m, 4H); 13C NMR (126 MHz, CD3OD) δ 166.3, 158.7, 135.1, 129.1,
128.3, 127.1, 58.3, 40.9, 39.3, 38.9, 31.7, 28.7, 23.3.
Figure 3. Some calculated physicochemical properties of the chemical space of macrocycles. A: cLogP over MW scatter plot, B: cLogP over MW box
plot, C: Lipinski RO5 radar plot, D: compound distribution based on Lipinski RO5.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b02984
J. Org. Chem. 2018, 83, 1441−1447
1444
N-(5-Aminopentyl)-4-isocyanobutanamide 3f. The product was
obtained as an oil (45%, 0.443 g). 1H NMR (500 MHz, CD3OD) δ
3.60−3.53 (m, 1H), 3.37−3.32 (m, 1H), 3.23 (t, J = 7.0 Hz, 1H),
2.99−2.90 (m, 2H), 2.39 (t, J = 8.4, 6.4 Hz, 1H), 2.05−1.97 (m, 2H),
1.77−1.67 (m, 2H), 1.65−1.55 (m, 2H), 1.51−1.41 (m, 2H), 1.34 (t, J
= 7.1 Hz, 1H), 1.28 (td, J = 7.2, 1.7 Hz, 1H). 13C NMR (126 MHz,
CD3OD) δ 172.9, 154.9, 40.6, 39.3, 38.6, 32.0, 28.5, 27.0, 25.1, 23.4.
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C10H20N3O 198.1601;
found 198.1600.
N-(6-Aminohexyl)-3-isocyanopropanamide 3g. The product was
obtained as an oil (42%, 0.413 g). 1H NMR (500 MHz, CD3OD) δ
3.83−3.72 (m, 1H), 3.38 (s, 2H), 3.36−3.32 (m, 1H), 3.25 (t, J = 7.0
Hz, 1H), 2.67 (t, J = 7.1, 0.9 Hz, 2H), 2.63−2.55 (m, 1H), 1.62−1.47
(m, 4H), 1.40 (m, 4H). 13C NMR (126 MHz, CD3OD) δ 170.0,
155.2, 41.0, 40.9, 39.0, 37.6, 35.1, 32.2, 32.1, 29.0. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd for C10H20N3O 198.1601; found 198.1599.
N-(2-((2-Aminoethyl)thio)ethyl)-3-isocyanopropanamide 3h. The
product was obtained as an oil (38%, 0.381 g). 1H NMR (500 MHz,
CDCl3) δ 6.96 (t, J = 5.7 Hz, 1H), 3.73 (t, J = 6.7, 3.4 Hz, 2H), 3.51−
3.45 (m, 2H), 2.92−2.87 (m, 2H), 2.72−2.63 (m, 4H), 2.62−2.55 (m,
2H). 13C NMR (126 MHz, CDCl3) δ 168.5, 156.8, 41.0, 39.0, 37.9,
35.9, 35.7, 31.6. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C8H15N3OS 202.1009; found 202.1008.
N-(2-((2-Aminoethyl)thio)ethyl)-5-isocyanopentanamide 3i. The
product was obtained as an oil (57%, 0.652 g). 1H NMR (500 MHz,
CDCl3) δ 6.52 (t, J = 5.6 Hz, 1H), 3.47−3.36 (m, 4H), 2.88 (t, J = 6.3
Hz, 2H), 2.71−2.58 (m, 4H), 2.23 (t, J = 7.0 Hz, 2H), 1.85−1.67 (m,
4H). 13C NMR (126 MHz, CDCl3) δ 172.2, 155.9, 41.4, 41.0, 38.7,
35.6, 35.2, 31.6, 28.5, 22.4. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C10H20N3OS 230.1322; found 230.1320.
N-(6-Aminohexyl)-6-isocyanohexanamide 3j. The product was
obtained as an oil (66%, 0.788 g). 1H NMR (500 MHz, CDCl3) δ 3.42
(tt, J = 6.6, 1.8 Hz, 1H), 3.22 (q, J = 6.7 Hz, 2H), 2.93−2.80 (m, 4H),
2.23 (t, J = 7.4 Hz, 1H), 1.76−1.58 (m, 6H), 1.57−1.44 (m, 5H),
1.43−1.35 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 173.0, 155.4,
41.5, 41.1, 40.6, 39.3, 36.2, 31.3, 29.9, 28.8, 26.1, 26.0, 24.8, 24.5.
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C13H26N3O 240.2070;
found 240.2069.
Procedure and Analytical Data for the Macrocyclization
Reactions. α-Isocyano-ω-amine (1.0 mmol) and aldehyde (1.0
mmol) were stirred at room temperature in MeOH (10 mL) for 1
h. The reaction was diluted to (0.01 M, 100 mL), and then the
carboxylic acid (1.0 mmol) was added. The mixture was stirred for 24
h. The solvent was removed under reduced pressure, and the residue
was puriﬁed using ﬂash chromatography (DCM:MeOH (9:1)).
4-(2-Phenylacetyl)-1,4,10-triazacyclopentadecane-2,11-dione
6a. The product was obtained as a white solid (60%, 0.215 g, mp
164−166 °C); 1H NMR (500 MHz, CDCl3) δ 7.66 (t, J = 7.0 Hz,
1H), 7.39−7.26 (m, 5H), 6.41 (t, J = 6.3 Hz, 1H), 3.96 (s, 2H), 3.79
(s, 2H), 3.47 (t, J = 6.0 Hz, 2H), 3.28 (q, J = 7.0 Hz, 2H), 3.18 (q, J =
5.6 Hz, 2H), 2.24 (t, J = 7.1 Hz, 2H), 1.67−1.55 (m, 4H), 1.53−1.44
(m, 4H), 1.10 (q, J = 7.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ
173.5, 172.9, 170.4, 134.5, 128.8, 128.8, 127.2, 53.0, 51.8, 40.8, 38.1,
36.8, 35.2, 28.7, 27.9, 27.8, 23.4, 23.1. HRMS (ESI-TOF) m/z: [M +
H]+ Calcd for C20H30N3O3 360.2282; found 360.2281.
4-(2-(4-Bromophenyl)acetyl)-3-isobutyl-1,4,10-triazacyclopenta-
decane-2,11-dione 6b. The product was obtained as a white solid
(51%, 0.251 g, mp 170−172 °C); 1H NMR (500 MHz, CDCl3) δ 7.44
(d, J = 8.3 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 6.59 (t, J = 6.1 Hz, 1H),
4.72 (s, 1H), 3.70 (d, J = 3.9 Hz, 2H), 3.55 (s, 1H), 3.44 (s, 1H),
3.39−3.30 (m, 2H), 3.14−2.81 (m, 2H), 2.34−2.13 (m, 2H), 1.88−
1.75 (m, 1H), 1.74−1.33 (m, 10H), 1.23 (m, 2H), 0.89 (dd, J = 11.2,
6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.5, 172.7, 172.1,
133.8, 131.8, 130.8, 121.1, 40.8, 40.7, 38.8, 36.9, 36.4, 35.1, 28.5, 28.0,
24.9, 24.4, 22.8, 22.7, 22.5. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C24H37N3O3Br 494.2013; found 494.2011.
3-(2-(Methylthio)ethyl)-4-(2-phenylacetyl)-1,4,8-triazacyclotetra-
decane-2,9-dione 6c. The product was obtained as a white solid
(50%, 0.209 g, mp 183−185 °C); A mixture of rotamers is observed
and the major of the rotamers taken ; 1H NMR (500 MHz, CDCl3) δ
7.46−7.29 (m, 3H), 7.29−7.20 (m, 2H), 6.10 (s, 1H), 4.85 (t, J = 7.3
Hz, 1H), 3.77 (s, 2H), 3.73−3.54 (m, 2H), 3.53−3.37 (m, 1H), 3.35−
3.20 (m, 1H), 3.18−2.96 (m, 2H), 2.57−2.34 (m, 3H), 2.34−2.21 (m,
2H), 2.12 (s, 3H), 2.08−1.92 (m, 2H), 1.86−1.58 (m, 3H), 1.45 (t, J =
11.1 Hz, 2H), 1.36−1.13 (m, 2H); 13C NMR (126 MHz, CDCl3) δ
173.6, 172.5, 170.7, 135.0, 129.3, 129.2, 127.5, 59.7, 53.4, 46.5, 41.9,
38.5, 37.8, 36.5, 31.2, 30.2, 29.4, 28.9, 24.2, 15.8. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd for C22H34N3O3S 420.2315; found 420.2313.
3-Isobutyl-4-(2-phenylacetyl)-1,4,8-triazacyclotetradecane-2,9-
dione 6d. The product was obtained as brown oil (74%, 0.296 g); 1H
NMR (500 MHz, CDCl3) δ 7.42−7.37 (m, 2H), 7.36−7.31 (m, 3H),
6.32 (dd, J = 15.3, 8.5 Hz, 1H), 5.69 (t, J = 6.1 Hz, 1H), 5.24−5.17 (m,
1H), 3.73 (s, 2H), 3.33−3.24 (m, 4H), 3.13−3.02 (m, 2H), 2.18 (t, J =
7.5, 1.9 Hz, 2H), 1.71 (dd, J = 7.2, 5.8 Hz, 2H), 1.66−1.59 (m, 5H),
1.35−1.27 (m, 2H), 1.27−1.19 (m, 2H), 0.92 (dd, J = 8.2, 6.3 Hz,
6H).; 13C NMR (126 MHz, CDCl3) δ 173.6, 170.9, 170.3, 133.6,
129.2, 128.9, 127.6, 73.0, 41.6, 40.8, 38.8, 36.4, 36.0, 35.8, 29.7, 28.9,
26.2, 25.1, 24.5, 23.1, 21.7. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C23H36N3O3 402.2751; found 402.2750.
2-(tert-Butyl)-1-(2-(4-nitrophenyl)acetyl)-1,4,8-triazacyclodode-
cane-3,7-dione 6e. The product was obtained as a white solid (36%,
0.150 g, mp 188−190 °C); 1H NMR (500 MHz, DMSO-d6) δ 8.29 (d,
J = 8.2 Hz, 1H), 8.21−8.16 (m, 2H), 7.56−7.52 (m, 2H), 4.67 (s, 1H),
4.21−3.97 (m, 2H), 3.85−3.67 (m, 2H), 3.56 (dd, J = 15.2, 8.4 Hz,
1H), 3.18−2.93 (m, 2H), 2.85 (d, J = 13.4 Hz, 1H), 2.38−2.26 (m,
1H), 2.26−2.11 (m, 1H), 1.80−1.64 (m, 1H), 1.50−1.35 (m, 1H),
1.35−1.17 (m, 1H), 1.12 (d, J = 18.4 Hz, 1H), 1.10−1.02 (m, 1H),
0.89 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 171.2, 171.0, 169.9,
146.7, 145.2, 131.5, 123.6, 37.9, 37.4, 37.3, 37.0, 36.9, 35.9, 28.2, 27.8,
27.1, 26.7. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C21H31N4O5
419.2289; found 419.2287.
2-(4-Chlorophenyl)-1-(2-phenylacetyl)-1,4,8-triazacyclodode-
cane-3,7-dione 6f. The product was obtained as a yellow oil (42%,
0.179 g); 1H NMR (500 MHz, CDCl3) δ 8.66 (t, J = 5.2 Hz, 1H),
7.39−7.31 (m, 3H), 7.31−7.25 (m, 2H), 7.24−7.17 (m, 2H), 7.17−
7.04 (m, 1H), 6.37 (t, J = 6.6 Hz, 1H), 3.77 (s, 2H), 3.55−3.39 (m,
4H), 3.28−3.07 (m, 2H), 2.69−2.52 (m, 2H), 1.47 (q, J = 3.6 Hz,
4H). 13C NMR (126 MHz, CDCl3) δ 177.6, 174.9, 171.9, 134.9, 129.3,
128.8, 128.7, 128.5, 127.0, 63.5, 45.9, 44.2, 38.8, 38.1, 35.4, 26.4, 26.1,
25.3. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C23H27N3O3Cl
428.1735; found 428.1734.
14-((1H-Indol-3-yl)methyl)-6-(2-phenylacetyl)-9-thia-6,12,15-
triazaspiro[4.11]hexadecane-13,16-dione 6g. The product was
obtained as a yellow solid (53%, 0.274 g, mp 180−182 °C);1H
NMR (500 MHz, CDCl3) δ 8.84 (d, J = 7.3 Hz, 1H), 8.18 (s, 1H),
7.66 (d, J = 7.9 Hz, 1H), 7.36 (s, 1H), 7.34 (d, J = 7.4 Hz, 2H), 7.29
(d, J = 2.6 Hz, 1H), 7.18 (t, J = 7.4 Hz, 3H), 7.15−7.10 (m, 2H), 6.79
(t, J = 6.0 Hz, 1H), 4.67−4.55 (m, 1H), 3.88 (s, 2H), 3.68 (s, 1H),
3.61−3.56 (m, 2H), 3.45 (dd, J = 15.0, 5.4 Hz, 1H), 3.24 (dd, J = 15.0,
8.9 Hz, 1H), 3.06−2.98 (m, 2H), 2.90−2.79 (m, 1H), 2.74−2.61 (m,
1H), 2.56−2.45 (m, 1H), 2.32−2.18 (m, 1H), 1.87−1.77 (m, 1H),
1.58−1.47 (m, 4H), 1.34−1.26 (m, 1H), 1.25−1.15 (m, 1H). 13C
NMR (126 MHz, CDCl3) δ 175.4, 173.8, 171.8, 136.3, 134.9, 129.4,
128.8, 128.7, 128.6, 127.3, 127.0, 123.2, 122.0, 119.4, 118.9, 111.1,
72.2, 54.9, 45.7, 43.7, 37.6, 37.2, 36.0, 35.5, 34.7, 26.2, 21.6, 21.0.
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C29H35N4O3S 519.2424;
found 519.2424.
3-Benzyl-6-(tert-butyl)-7-(2-phenylacetyl)-1,4,7-triazacyclotride-
cane-2,5-dione 6h. The product was obtained as a white oil (33%,
0.157 g); 1H NMR (500 MHz, CDCl3) δ 7.45−7.33 (m, 5H), 7.34−
7.21 (m, 3H), 4.75 (s, 1H), 3.99 (s, 2H), 3.68 (d, J = 5.2 Hz, 4H), 3.38
(s, 1H), 3.20−3.08 (m, 2H), 1.63−1.49 (m, 3H), 1.46−1.39 (m, 2H),
1.28 (d, J = 2.9 Hz, 1H), 1.24−1.20 (m, 3H), 1.15−1.09 (m, 4H), 1.07
(s, 9H). 13C NMR (126 MHz, CDCl3) δ 190.3, 183.6, 134.0, 129.0,
128.7, 127.6, 70.2, 52.0, 47.0, 40.7, 36.4, 35.7, 29.8, 28.6, 26.5, 26.4,
26.2, 26.2. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C29H40N3O3
478.2912; found 478.2912.
2-Isobutyl-1-(2-phenylacetyl)-1,4,9-triazacyclotetradecane-3,8-
dione 6i. The product was obtained as a yellow oil (45%, 0.180 g); 1H
NMR (500 MHz, CDCl3) δ 7.39−7.32 (m, 5H), 7.18 (d, J = 5.9 Hz,
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b02984
J. Org. Chem. 2018, 83, 1441−1447
1445
1H), 5.56 (t, J = 6.4 Hz, 1H), 4.26 (s, 1H), 3.83 (d, J = 5.9 Hz, 2H),
3.62−3.54 (m, 2H), 3.32 (q, J = 5.3 Hz, 2H), 3.18−3.11 (m, 1H),
3.07−2.99 (m, 1H), 2.43−2.34 (m, 1H), 2.26−2.19 (m, 1H), 2.15−
2.08 (m, 1H), 1.87 (t, J = 7.2 Hz, 2H), 1.81−1.74 (m, 1H), 1.53−1.48
(m, 2H), 1.46−1.42 (m, 1H), 1.37−1.32 (m, 1H), 1.29−1.26 (m, 1H),
1.23 (d, J = 6.0 Hz, 1H), 1.01 (t, J = 6.5 Hz, 1H), 0.90 (d, J = 6.2 Hz,
6H). 13C NMR (126 MHz, CDCl3) δ 173.2, 172.8, 172.4, 134.9, 128.9,
128.7, 127.0, 61.1, 48.9, 41.5, 40.7, 37.5, 37.2, 35.2, 29.1, 28.6, 25.0,
23.8, 23.1, 23.0, 22.1. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C23H36N3O3 402.2751; found 402.2750.
2-(4-Isopropylphenyl)-1-(2-phenylacetyl)-1,4,8-triazacyclotetra-
decane-3,7-dione 6j. The product was obtained as a white solid (39%,
0.180 g, mp 166−168 °C); 1H NMR (500 MHz, CDCl3) δ 7.40−7.29
(m, 3H), 7.28 (s, 1H), 7.24−7.12 (m, 5H), 6.65 (s, 1H), 5.60 (s, 1H),
3.93−3.60 (m, 4H), 3.62−3.39 (m, 3H), 3.28 (d, J = 51.2 Hz, 2H),
3.04−2.80 (m, 1H), 2.73−2.35 (m, 2H), 1.77−1.48 (m, 4H), 1.41 (s,
2H), 1.25 (d, J = 7.1 Hz, 6H), 1.23 (s, 2H). 13C NMR (126 MHz,
CDCl3) δ 172.8, 171.8, 171.0, 129.8, 129.2, 129.1, 128.9, 128.1, 127.3,
127.1, 126.9, 65.7, 49.8, 42.1, 39.8, 36.8, 36.0, 34.1, 29.0, 26.8, 26.5,
25.6, 24.2. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C28H38N3O3
464.2908; found 464.2906.
1-(3-Phenylpropanoyl)-1,4,8-triazacyclotetradecane-3,7-dione
6k. The product was obtained as a white solid (44%, 0.157 g, mp 177−
179 °C); 1H NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.5 Hz, 2H), 7.25
(q, J = 9.3, 7.9 Hz, 3H), 6.39 (t, J = 5.9 Hz, 1H), 4.01 (s, 2H), 3.54 (q,
J = 5.9 Hz, 2H), 3.39−3.29 (m, 4H), 3.02 (t, J = 7.8 Hz, 2H), 2.71 (t, J
= 7.9 Hz, 2H), 2.50 (t, J = 5.8 Hz, 2H), 1.63−1.51 (m, 4H), 1.44−1.36
(m, 2H), 1.28−1.20 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 173.8,
170.9, 170.6, 141.0, 128.6, 128.5, 126.3, 52.3, 50.6, 39.3, 36.3, 35.6,
35.3, 31.2, 28.4, 26.7, 26.3, 25.5. HRMS (ESI-TOF) m/z: [M + H]+
Calcd for C20H30N3O3 360.2282; found 360.2279.
4-(2-Phenylacetyl)-1-thia-4,7,11-triazacyclotridecane-6,10-dione
6l. The product was obtained as a white solid (62%, 0.216 g, mp 173−
174 °C); 1H NMR (500 MHz, DMSO-d6) δ 8.53−8.43 (m, 1H), 8.42
(d, J = 6.1 Hz, 1H), 7.35−7.26 (m, 2H), 7.27−7.18 (m, 3H), 3.98 (s,
2H), 3.81 (s, 2H), 3.36−3.25 (m, 6H), 2.69 (m, 2H), 2.63−2.58 (m,
2H), 2.41 (t, J = 5.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ
171.6, 170.9, 169.7, 136.5, 129.8, 128.6, 126.7, 52.4, 48.6, 42.6, 40.6,
36.2, 34.5, 30.8, 29.8. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C17H24N3O3S 350.1533; found 350.1532.
4-(2-(4-Bromophenyl)acetyl)-1-thia-4,7,13-triazacyclopentade-
cane-6,12-dione 6m. The product was obtained as a white solid
(58%, 0.264 g, mp 196−198 °C); 1H NMR (500 MHz, CDCl3) δ
7.48−7.44 (m, 2H), 7.44−7.40 (m, 1H), 7.19−7.13 (m, 2H), 7.11 (d, J
= 8.2 Hz, 2H), 3.98 (s, 2H), 3.77 (s, 2H), 3.67 (t, J = 6.2 Hz, 2H), 3.57
(d, J = 3.4 Hz, 1H), 3.46−3.37 (m, 2H), 3.33−3.22 (m, 2H), 2.90 (t, J
= 6.2 Hz, 2H), 2.83−2.75 (m, 2H), 2.29 (t, J = 6.3 Hz, 2H), 1.67−1.57
(m, J = 5.7, 4.8 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 174.3, 172.3,
170.4, 133.3, 131.9, 130.8, 121.3, 53.1, 50.1, 40.0, 37.9, 36.7, 34.4, 31.4,
30.4, 27.8, 22.5. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C19H27N3O3SBr 456.0949; found 456.0949.
6-(2-(p-Tolyl)acetyl)-9-thia-6,12,18-triazaspiro[4.14]nonadecane-
13,19-dione 6n. The product was obtained as a yellow solid (69%,
0.307 g, mp 195−197 °C); 1H NMR (500 MHz, CDCl3) δ 8.16 (s,
1H), 7.12 (s, 4H), 6.66 (s, 1H), 3.76 (s, 2H), 3.67−3.56 (m, 2H),
3.48−3.36 (m, 2H), 3.32−3.18 (m, 2H), 2.79−2.61 (m, 6H), 2.31 (s,
3H), 2.21 (t, J = 7.2 Hz, 2H), 1.87−1.71 (m, 2H), 1.71−1.55 (m, 6H),
1.49 (dd, J = 7.8, 5.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 174.0,
173.3, 136.6, 131.5, 129.3, 128.5, 72.5, 45.9, 42.6, 39.9, 37.1, 36.0, 34.8,
31.9, 27.8, 22.5, 21.7, 20.9. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C24H36N3O3S 446.2472; found 446.2471.
4-(2-(4-Bromophenyl)acetyl)-3-(2-(methylthio)ethyl)-1,4,11-tria-
zacycloheptadecane-2,12-dione 6o. The product was obtained as a
yellow oil (34%, 0.183 g). A mixture of rotamers was observed, and the
major rotamer analyzed: 1H NMR (500 MHz, CDCl3) δ 7.53 (t, J =
8.8 Hz, 2H), 7.27 (dd, J = 7.9, 5.1 Hz, 2H), 7.20 (d, J = 8.2 Hz, 1H),
6.25 (s, 1H), 5.49 (t, J = 6.2 Hz, 1H), 4.96 (s, 1H), 3.85−3.77 (m,
1H), 3.73 (d, J = 15.1 Hz, 1H), 3.54−3.46 (m, 1H), 3.42−3.34 (m,
1H), 3.22−3.10 (m, 1H), 3.08−2.90 (m, 2H), 2.66−2.53 (m, 1H),
2.51−2.41 (m, 2H), 2.41−2.27 (m, 1H), 2.10 (s, 3H), 2.02−1.89 (m,
1H), 1.84−1.71 (m, 3H), 1.60−1.43 (m, 7H), 1.41−1.23 (m, 7H).13C
NMR (126 MHz, CDCl3) δ 173.0, 172.6, 171.1, 133.8, 131.9, 131.0,
121.1, 59.6, 46.5, 40.3, 39.4, 37.7, 36.2, 30.8, 29.7, 29.7, 28.8, 27.8,
26.7, 25.6, 25.0, 24.2, 15.4. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C25H39N3O3SBr 540.1890; found 540.1890.
General Procedure and Analytical Data for the Synthesis of
Sulfoxide Macrocycle. Macrocycle 6q (1.0 mmol) was dissolved in 1
mL of DCM, and m-chloroperoxybenzoic acid (1 equiv) was added.
The solution stirred at room temperature for 4 h. After completion of
the reaction, the solvent was removed under reduced pressure and the
residue was puriﬁed using ﬂash chromatography (DCM:MeOH
(9:1)).
4-(2-(4-Bromophenyl)acetyl)-1-thia-4,7,13-triazacyclopentade-
cane-6,12-dione 1-Oxide 7a. The product was obtained as a white
solid (65%, 0.264 g, mp 205−207 °C); 1H NMR (500 MHz,
methanol-d4) δ 7.36 (dd, J = 17.7, 8.0 Hz, 2H), 7.13 (d, J = 8.1 Hz,
1H), 7.06 (d, J = 8.0 Hz, 1H), 5.27−5.23 (m, 4H), 5.17 (s, 2H), 3.82
(s, 1H), 3.74 (s, 1H), 3.50 (d, J = 8.8 Hz, 2H), 3.23−3.14 (m, 5H),
2.18−2.05 (m, 2H), 1.59−1.33 (m, 4H). 13C NMR (126 MHz,
methanol-d4) δ 173.1, 172.0, 168.6, 134.6, 133.2, 130.0, 126.6, 125.4,
118.8, 61.2, 54.5, 51.8, 51.7, 35.7, 35.4, 26.0, 22.0, 17.6. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C19H27N3O4SBr 472.0900; found
472.0901.
General Procedure and Analytical Data for the Synthesis of
Sulfone Macrocycle. Macrocycle 6q (1.0 mmol) was dissolved in 1
mL of DCM, and m-chloroperoxybenzoic acid (4 equiv) was added.
The solution stirred at room temperature for 4 h. After completion of
the reaction, the solvent was removed under reduced pressure and the
residue was puriﬁed using ﬂash chromatography (DCM:MeOH
(9:1)).
4-(2-(4-Bromophenyl)acetyl)-1-thia-4,7,13-triazacyclopentade-
cane-6,12-dione 1,1-Dioxide 7b. The product was obtained as a white
solid (77%, 0.375 g, mp 211−212 °C); 1H NMR (500 MHz, DMSO-
d6) δ 7.81 (d, J = 17.2 Hz, 1H), 7.65 (s, 1H), 7.35 (dd, J = 16.2, 7.9
Hz, 2H), 7.14 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 3.99 (d, J
= 22.7 Hz, 2H), 3.86−3.72 (m, 2H), 3.54 (d, J = 14.6 Hz, 3H), 3.38 (t,
J = 7.6 Hz, 1H), 3.30 (d, J = 7.7 Hz, 1H), 3.27−3.09 (m, 5H), 2.57−
2.51 (m, 1H), 2.12 (d, J = 7.3 Hz, 2H), 1.63−1.37 (m, 4H). 13C NMR
(126 MHz, DMSO-d6) δ 174.6, 172.5, 169.7, 140.1, 132.4, 132.1,
132.0, 125.0, 55.2, 54.9, 53.2, 52.9, 43.1, 40.6, 38.6, 36.0, 34.8, 29.4,
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